Chemo plus immunotherapy and hyperbaric oxygen for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy (XELOX), an immunotherapy drug (Sintilimab), and hyperbaric oxygen therapy for people with advanced or metastatic stomach or gastroesophageal junction cancer. The goal is to see if this triple therapy helps shrink or control the cancer better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with adenocarcinoma of the stomach or where the stomach meets the esophagus.
- Your cancer has spread to other parts of the body or come back after previous treatment.
- You have not had any previous cancer treatments like chemotherapy, radiation, or immunotherapy for advanced disease.
- You are between 18 and 75 years old.
- You are able to perform daily activities with little or no help (ECOG score 0 or 1).
- You have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares three different treatment combinations for advanced stomach cancer that hasn't spread to the brain and is HER2-negative. It includes an immunotherapy drug (sintilimab) with different chemotherapy backbones, and one option adds a targeted therapy (lenvatinib). The goal is to see which combination works best and has acceptable side effects.
This trial tests whether adding two newer drugs (pucotenlimab and lenvatinib) to standard chemotherapy (SOX) works better than chemotherapy alone for people with advanced stomach or gastroesophageal junction cancer that is HER2-negative. The goal is to see if the combination slows cancer growth.
This Phase 1/2 trial tests a combination treatment for advanced or metastatic stomach and food-pipe (gastroesophageal junction) cancer: a chemotherapy regimen (CapeOX) plus the immunotherapy drug sintilimab and the targeted drug bevacizumab. It aims to see how well this combination controls the cancer and how safely it can be given.
This trial tests a new approach for locally advanced stomach cancer. It uses a heated chemotherapy bath (HIPEC) before giving a combination of two chemotherapy drugs (SOX or XELOX) plus an immunotherapy drug called serplulimab. This aims to shrink the tumor and improve the chances of successful surgery and long-term control.
This phase 3 study compares two versions of a first-time treatment for HER2-negative advanced stomach or gastroesophageal cancer, both including immunotherapy (sintilimab). It looks for a safer or more effective way to slow cancer growth or improve outcomes.
This trial tests a combination of two immunotherapy drugs (ipilimumab and sintilimab) with chemotherapy (modified XELOX) as a first treatment for stomach cancer that cannot be removed by surgery. The goal is to see if this combination can shrink the tumor enough to allow surgery later.
Hear when a new Gastric (Stomach) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.